Increased levels of CA 125 and CA 19.9 serum tumour markers following cyclic combined hormone replacement therapy

Journal of Clinical Pharmacy and Therapeutics

Volumn 34, Issue 1, 2009, Pages 129-132

  Cecchi, E ^a,b   Lapi, F ^a   Vannacci, A ^a   Banchelli, G ^a   Mazzei, T ^a   Mugelli, A ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b ASL 4 Hospital   (Italy)

Author keywords

CA 125; CA 19.9; Cyclic hormone replacement therapy; Tumour markers

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; CYPROTERONE ACETATE; DAIDZEIN; ESTRADIOL; ESTROGEN; GENISTEIN; GLYCITEIN; PHYTOESTROGEN;

ADULT; ARTICLE; CASE REPORT; DIAGNOSTIC ERROR; ENDOCRINE DISEASE; ESTROGEN ACTIVITY; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; POSTMENOPAUSE; RADIODIAGNOSIS; SIDE EFFECT; UTERUS MYOMA;

CA-125 ANTIGEN; CA-19-9 ANTIGEN; CYPROTERONE ACETATE; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; PHYTOESTROGENS; POSTMENOPAUSE; TUMOR MARKERS, BIOLOGICAL;

EID: 58149280201     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2008.00995.x     Document Type: Article

References (16)

1. Gadducci A, Cosio S, Carpi A et al. (2004) Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomedicine & Pharmacotherapy, 58, 24 38.
2. Cengiz B, Atabekoglu C, Cetinkaya E et al. (2003) Effect of hormone replacement therapy on serum levels of tumor markers in healthy postmenopausal women. Maturitas, 46, 301 306.
3. Sevinc A, Buyukberber S, Sari R et al. (2000) Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids. Gynecologic Oncology, 77, 254 257.
4. Giannini E, Borro P, Botta F et al. (2000) Cholestasis is the main determinant of abnormal CA 19-9 levels in patients with liver cirrhosis. International Journal of Biological Markers, 15, 226 230.
5. Schoniger-Hekele M, Muller C (2006) The combined elevation of tumor markers CA 19-9 and CA 125 in liver disease patients is highly specific for severe liver fibrosis. Digestive Diseases and Sciences, 51, 338 345.
6. Atabekoglu C, Bozaci EA, Tezcan S (2005) Elevated carbohydrate antigen 19-9 in a dermoid cyst. International Journal of Gynaecology and Obstetrics, 91, 262 263.
7. Kurata H, Sasaki M, Kase H et al. (2002) Elevated serum CA125 and CA19-9 due to the spontaneous rupture of ovarian endometrioma. European Journal of Obstetrics, Gynecology and Reproductive Biology, 105, 75 76.
8. Dede M, Gungor S, Yenen MC et al. (2006) CA19-9 may have clinical significance in mature cystic teratomas of the ovary. International Journal of Gynecological Cancer, 16, 189 193.
9. Atabekoglu CS, Sonmezer M, Aydinuraz B et al. (2003) Extremely elevated CA 125 level due to an unruptured large endometrioma. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 110, 105 106.
10. Pauler DK, Menon U, McIntosh M et al. (2001) Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiology, Biomarkers & Prevention, 10, 489 493.
11. Kelly WN, Arellano FM, Barnes J et al. (2007) Guidelines for submitting adverse event reports for publication. Drug Safety, 30, 367 373.
12. Atabekoglu C, Sonmezer M, Dunder I (2003) Elevated serum CA 125 and CA 19-9 due to spontaneous rupture of endometrioma [Eur J Obstet Gynecol Reprod Biol 2002;105:75-6]. European Journal of Obstetrics, Gynecology and Reproductive Biology, 109, 112.
13. Naranjo CA, Busto U, Sellers EM et al. (1981) A method for estimating the probability of adverse drug reactions. Clinical Pharmacology and Therapeutics, 30, 239 245.
14. Karabacak O, Ilgin N, Tiras B et al. (2002) Influence of exogenous estrogen administration on serum CA-125 originating from the endometrium. International Journal of Gynaecology and Obstetrics, 76, 169 172.
15. Caserta D, Maranghi L, Mantovani A et al. (2008) Impact of endocrine disruptor chemicals in gynaecology. Human Reproduction, 14, 59 72.
16. Bond C, Hannaford P (2003) Issues related to monitoring the safety of over-the-counter (OTC) medicines. Drug Safety, 26, 1065 1074.